Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 5/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15914361 | 1.00 | LTA4H (0.40) | LTA4HMEN1ALDH1A1CYP2D6RAB9A | |
| SCHEMBL14672244 | 1.00 | LTA4H (0.40) | LTA4HMEN1ALDH1A1CYP2D6RAB9A | |
| SCHEMBL15914362 | 1.00 | LTA4H (0.40) | LTA4HMEN1ALDH1A1CYP2D6RAB9A | |
| SCHEMBL15751312 | 0.99 | LTA4H (0.39) | LTA4HMEN1ALDH1A1CYP2D6RAB9A | |
| SCHEMBL15751313 | 0.84 | LTA4H (0.35) | LTA4HMEN1ALDH1A1CYP2D6RAB9A | |
| SCHEMBL15751314 | 0.84 | LTA4H (0.35) | LTA4HMEN1ALDH1A1CYP2D6RAB9A | |
| SCHEMBL15751310 | 0.84 | LTA4H (0.35) | LTA4HMEN1ALDH1A1CYP2D6RAB9A | |
| SCHEMBL15914403 | 0.83 | CYP2D6 (0.36) | LTA4HMEN1ALDH1A1CYP2D6RAB9A | |
| SCHEMBL15914400 | 0.83 | CYP2D6 (0.36) | LTA4HMEN1ALDH1A1CYP2D6RAB9A | |
| SCHEMBL15914401 | 0.83 | CYP2D6 (0.36) | LTA4HMEN1ALDH1A1CYP2D6RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9115079-B2 | NDM inhibitor | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2015-08-25 | — | — | US | disclosed |
| US-20140221330-A1 | NDM INHIBITOR | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221330-A1 | NDM INHIBITOR | MGAM, NQO1, NQO2 | LTA4H 639/4885MEN1 3376/4885ALDH1A1 342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.